VivoSeq
Other

Nocturia

0

Pipeline Programs↗

0

Active Trials↗

2

Companies Involved↗

Nocturia is an early-stage landscape with 0 programs across 2 companies. The most active players are Serenity Pharmaceuticals, Inc., Ferring.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

75/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Serenity Pharmaceuticals, Inc.

0 programs

PreclinicalFerring logo

Ferring

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

8

clinical trials

Completed6 · 75%
Terminated1 · 13%
Withdrawn1 · 13%

Clinical Trials

Trial Activity

8 trials

Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia - DB4
Completed·SSerenity Pharmaceuticals, Inc.·Phase 3·NCT01900704·810 enrolled
Long Term Safety Assessment of SER120 in Patients With Nocturia
Completed·SSerenity Pharmaceuticals, Inc.·Phase 3·NCT00981682·376 enrolled
Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary
Completed·Ferring logoFerring·Phase 3·NCT01552343·56 enrolled
Specified Drug Use-results Survey (Long-term Use) on MINIRINMELT® OD Tablet (Nocturia)
Completed·Ferring logoFerring·N/A·NCT04329975·1,087 enrolled
Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia
Completed·SSerenity Pharmaceuticals, Inc.·Phase 2/3·NCT01357356·750 enrolled
Dose Range Finding Study of Fedovapagon in Men With Nocturia
Completed·VVantia Ltd·Phase 2·NCT01656239·358 enrolled
Study of Minirin Melt® in Adult Patients With Nocturia
Terminated·Ferring logoFerring·N/A·NCT03089073·835 enrolled
Exploratory Study Evaluating the Effects of Darifenacin on Nocturia, Sleep and Daytime Wakefulness
Withdrawn·CCognitive Research Corporation·Phase 4·NCT01018225

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)